ovarian hyperstimulation syndrome


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

ovarian hyperstimulation syndrome

iatrogenic development of ovarian hyperstimulation that occurs when the luteotropic effects of human chorionic gonadotropin are exaggerated in a cycle in which ovarian stimulation has been done as a component of infertility treatment. The human chorionic gonadotropin is administered exogeneously to trigger ovulation after gonadotropin stimulation. It is present endogenously after implantation. Syndrome includes, to varying degrees, abdominal distention, potentially massive ovarian enlargement, and third spacing of vascular volume. It can range from moderate discomfort to life-threatening ovarian enlargement and fluid shifts.

ovarian hyperstimulation syndrome

,

OHSS

A potentially life-threatening complication that may occur in women receiving drugs to stimulate ovulation. The acute onset occurs within the first week ovulation is induced and is characterized by marked cystic ovarian enlargement, ascites, hydrothorax, arterial hypotension, tachycardia, hemoconcentration, oliguria, sodium retention, hypernatremia, and in severe cases renal failure. The condition is usually mild if the diameter of the ovary is less than 8 cm; moderate if 8 to 12 cm; and severe if greater than 12 cm.

Treatment includes symptomatic therapy to maintain circulatory function, bedrest, a low-sodium diet, and diuretic therapy. The life-threatening possibility can be avoided with close monitoring and withholding of drugs if ovarian response becomes excessive.

ovarian hyperstimulation syndrome

Ovarian enlargement, the production of multiple ovarian cysts, increased capillary permeability with generalized oedema and intravascular fluid depletion, SHOCK, and sometimes even death. The syndrome, which is uncommon, is caused by gonadotropin medical treatment to stimulate ovulation. Rarely, it may occur spontaneously during pregnancy as a result of a mutation in the gene for the follicle-stimulating hormone receptor.
References in periodicals archive ?
Early timed follicular aspiration prevents severe ovarian hyperstimulation syndrome.
Elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome may not prevent the condition but reduces the live birth rate.
Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program.
Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.
The most frequently reported adverse drug reactions during treatment with corifollitropin alfa in clinical trials are Ovarian Hyperstimulation Syndrome (OHSS), pelvic pain and discomfort, headache, nausea, fatigue and breast complaints (including tenderness).
Two significant risks associated with ovulation induction treatment are ovarian hyperstimulation syndrome (OHSS) and multiple births.
Ovarian hyperstimulation syndrome, painful ovarian enlargement, is another potential complication that may result from an overly vigorous response to ovulation medications.
This could result in a safer, more controlled stimulation cycle with a lower risk of multiple pregnancies, excessive response, and ovarian hyperstimulation syndrome (OHSS), which is excessive stimulation of the ovaries.
Ovarian hyperstimulation syndrome (OHSS) with or without vascular and pulmonary complications, can occur with the use of infertility drugs.
Like all gonadotropins, Bravelle(R) is a potent substance capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (incidence of 6.
Like all gonadotropins, Bravelle(TM) is a potent substance capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (incidence of 6.
Ovarian hyperstimulation syndrome (OHSS), with or without vascular and pulmonary complications, can occur with the use of fertility drugs.